Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S and GlaxoSmithKline Submit sBLA for Arzerra (Ofatumumab) to US Regulatory Authorities


Friday, 18 Oct 2013 04:18pm EDT 

Genmab A/S and GlaxoSmithKline (GSK) announced that a supplemental Biologics License Application (sBLA) has been submitted to the US Food and Drug Administration (FDA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy. The application is based on results from an international, multi-center, randomized Phase III study of Arzerra in combination with chlorambucil versus chlorambucil alone in more than 400 patients with previously untreated CLL. 

Company Quote

352.7
-1.4 -0.40%
19 Dec 2014